NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers |
PAR-23-287 (K99/R00 - Independent Clinical Trial Required) |
R00, K99 |
Clinical Trial Required |
10/15/2026 |
|
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers |
PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required) |
R00, K99 |
|
10/15/2026 |
|
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed) |
UH2, UH3 |
Clinical Trial Not Allowed |
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-25-075 (UH3 Clinical Trials Not Allowed) |
UH3 |
|
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |
Cancer Prevention and Control Clinical Trials Grant Program |
PAR-25-167 (R01 Clinical Trial Required) |
R01 |
Clinical Trial Required |
01/08/2027 |
Goli Samimi, Ph.D., M.P.H. |
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-25-070 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
01/08/2027 |
Edward Sauter, M.D., Ph.D. |
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-25-069 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
01/08/2027 |
Edward Sauter, M.D., Ph.D. |
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis |
PAR-25-081 (R01 Clinical Trial Required) |
R01 |
Clinical Trial Required |
01/08/2027 |
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
HEAL Initiative: Studies to Enable Analgesic Discovery |
RFA-NS-25-023 (R61/R33 - Clinical Trial Not Allowed) |
R61, R33 |
Clinical Trial Not Allowed |
01/16/2027 |
Rachel Altshuler, Ph.D. |
The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research |
PAR-24-153 (K12 Clinical Trial Optional) |
K12 |
Clinical Trial Optional |
02/19/2027 |
Brandy Heckman-Stoddard, Ph.D., M.P.H. |